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T cell persistence is likely to promote long-term anti-
tumor effects after adoptive T cell transfer. We have
recently shown that incorporation of the ICOS intracellu-
lar domain into chimeric antigen receptors (CARs) signifi-
cantly increased Th17 cell persistence in vivo, compared
to CARs with CD28 or 4-1BB intracellular domains [1].
Here, we hypothesized that CD4+ and CD8+ T cells
require distinct cytokine and costimulation signals for
optimal persistence. To test this hypothesis, we compared
the in vivo antitumor effects and persistence of combined
CD4+ T cells (bulk or Th17-polarized) and CD8+ T cells
redirected with CARs containing CD28, 4-1BB or ICOS-
based costimulatory domains. Using multiple mouse
tumor models, we demonstrate that the ICOS intracellular
domain significantly enhanced the in vivo persistence of
CAR-expressing CD4+ T cells, and that both persistence
and tumor infiltration were further enhanced by culturing
these cells under Th17-polarizing conditions. Importantly,
Th17-polarized CD4+ T cells expressing an ICOS-based
CAR significantly increased the circulatory persistence of
bulk CD8+ T cells expressing either CD28- or 4-1BB-
based CARs. We further demonstrate that the antitumor
effect of CAR-expressing CD8+ T cells was enhanced
when co-injected with ICOS-redirected Th17 cells. Collec-
tively, our data suggest that combining Th17 CD4+ T cells
redirected with an ICOS-based CAR with CD8+ CAR-T
cells will enhance their persistence and antitumor efficacy.
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